BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NKT5097 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NKT5097\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07029399-9065@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:NKT5097: Phase 1 readout est. (NCT07029399)
DESCRIPTION:NKT5097\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors\nEs
 timated primary completion: 31 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nkt5097#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07029399
URL:https://assetmemo.bio/drug/nkt5097#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
